sprite-preloader
Dienstag, 31.03.2015 Börsentäglich über 12.000 News von 508 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: 935166 ISIN: SE0000221723 Ticker-Symbol: M5E 
Aktie:
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MEDA AB Chart 1 Jahr
1-Woche-Intraday-Chart
MEDA AB 1-Woche-Intraday-Chart

Aktuelle News zu MEDA Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
MoMEDA: Invitation to Meda's Capital Markets Day on May 12, 20151
Regulatory News: Meda (STO:MEDAA)(Pink Sheets:MDABY) invites analysts, investors and media to a Capital Markets Day on May 12 at the head office in Solna. Presentations will start...
► Artikel lesen
MoMeda: Madaus war gestern7

► Artikel lesen
MEDA Aktie jetzt ab 2,99 Euro handeln!

► Artikel lesen
17.03.MEDA: Nomination Committee's Proposal for Composition of the Board8
Regulatory News: Meda AB's (STO:MEDAA) (Pink Sheets:MDABY) Nomination Committee proposes the election of Kimberly Lein-Mathisen and Lillie Li Valeur as new Board members. The committee...
► Artikel lesen
20.02.MEDA: DYMISTA approved in children 6 to 11 years of age with seasonal allergic rhinitis14
Regulatory News: Meda announces the approval by FDA (U.S. Food and Drug Administration) of Dymista, a single formulation azelastine hydrochloride and fluticasone propionate nasal...
► Artikel lesen
11.02.MEDA: Year-end Report, January-December 201433
Regulatory News: MEDA: (STO:MEDAA)(Pink Sheets:MDABY) January-December 2014[1] Net sales reached SEK 15,352 million (13,114), corresponding to an increase of 12%...
► Artikel lesen
05.02.MEDA: Invitation to Teleconference for Analysts, Investors and Journalists16
Presentation of Meda's Year-End Results 2014 On Wednesday, February 11th, 2015 at 8:00 CET, Meda will release its Year-End Results for 2014. Meda invites all analysts, investors and...
► Artikel lesen
29.01.BioDelivery Signs Agreement with Meda for Onsolis16

► Artikel lesen
06.01."Fressen oder gefressen werden": Pharmakonzern Meda will weiter zukaufen57

► Artikel lesen
02.01.Meda launches $276M rights issue to help pay for Rottapharm18

► Artikel lesen
30.12.Meda Reports Change In Number Of Shares, Votes3

► Artikel lesen
30.12.Change in Number of Shares and Votes in Meda6
Regulatory News: The rights issue recently conducted by Meda AB (STO:MEDA-A) (Pink Sheets:MDABY) has resulted in an increase of shares and votes during December 2014 of in total 33...
► Artikel lesen
10.12.MEDA: Meda's rights issue fully subscribed17
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia, Japan, Hong Kong, New Zealand, South Africa...
► Artikel lesen
09.12.MEDA and Mountain Lion Agriculture Win 2014 Social Finance Innovator Award for Investments Making Positive Social/Environmental Impacts11
WATERLOO, ON--(Marketwired - December 09, 2014) - MEDA -- Mennonite Economic Development Associates -- and Mountain Lion Agriculture (MLA) were recognized on November...
► Artikel lesen
03.12.Cipla, Meda Sue Apotex To Enforce Dymista Patents8

► Artikel lesen
03.12.Meda Pharma, Cipla Sue Apotex To Enforce Dymista Patents2

► Artikel lesen
03.12.Meda and Cipla sue Apotex to enforce Dymista patents15
Regulatory News: Meda Pharmaceuticals Inc. and Cipla Ltd. today announced that they sued Apotex Inc. and Apotex Corp. ("Apotex") in Federal District Court in Delaware to enforce the...
► Artikel lesen
21.11.Madaus: Warten auf Meda49

► Artikel lesen
14.11.NASDAQ OMX Stockholm AB: Listing of subscription rights and paid subscription shares in Meda AB (167/14)17
With effect from November 19, 2014, the subscription rights in Meda AB will be quoted on the list for Equity rights. Quotation will continue up until and including December 2, 2014. Instrument: ...
► Artikel lesen
14.11.MEDA: Prospectus Concerning Meda's Rights Issue Published15
Regulatory News: Meda: (STO:MEDA-A) (Pink Sheets:MDABY) Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia...
► Artikel lesen
11.11.NASDAQ OMX Stockholm AB: Adjustment of warrants in Meda due to rights issue8
In connection with rights issueall warrants with Meda AB as underlying instrument will be recalculated. The recalculation will be effective as from November 12, 2014. Please see the attached sheets...
► Artikel lesen
Seite:  Weiter >>
70 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
MEDA AB-Investoren interessieren sich auch für diese News

Unternehmen / AktienAktienkurs%Top-Nachrichten
NOVARTIS93,50+1,71 %DGAP-Adhoc: Cytos Biotechnology AG: Novartis kauft CAD106 Lizenzvertrag für CHF 4 Mio. aus
Cytos Biotechnology AG: Novartis kauft CAD106 Lizenzvertrag für CHF 4 Mio. aus EQS Group-Ad-hoc: Cytos Biotechnology AG / Schlagwort(e): Vereinbarung Cytos Biotechnology AG: Novartis kauft CAD106 Lizenzvertrag...
► Artikel lesen
NOVO NORDISK50,22+1,66 %Novo Nordisk A/S: Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US
Bagsværd, Denmark, 26 March 2015 - Novo Nordisk today announced that the company has decided to submit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New...
► Artikel lesen
SANOFI92,97+1,31 %Evotec-Aktie: gemischte Geschäftszahlen, Abschluss der Allianz mit Sanofi steht bevor! - Aktienanalyse
Frankfurt - Evotec-Aktienanalyse von Aktienanalyst Igor Kim von Oddo Seydler: Im Rahmen einer aktuellen Aktienanalyse empfiehlt Igor Kim, Aktienanalyst von Oddo Seydler, die Aktien des Hamburger Wirkstoffforschers...
► Artikel lesen
ASTRAZENECA64,50+0,84 %AstraZeneca: FDA Approves New Administration Option For BRILINTA
LONDON (dpa-AFX) - AstraZeneca (AZN) announced the US FDA has approved a new administration option for acute coronary syndrome patients who are unable to swallow BRILINTA 90 mg tablets whole....
► Artikel lesen
MYLAN54,70-4,83 %Aktien im Fokus - Donnerstag, der 26.03.2015 - DAX, ALLIANZ, BAYER, MYLAN, REGENERON PHARMA, DANAHER, HERTZ GLOBAL, KINDER MORGAN

► Artikel lesen
Lade...